Key terms

About MCK

McKesson Corp. engages in providing healthcare services. It operates through the following segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs. The RxTS segment offers prescription price transparency, benefit insight, dispensing support services, third-party logistics, and wholesale distribution. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The International segment refers to the distribution and services to wholesale, institutional, and retail customers in Europe and Canada. The company was founded by John McKesson and Charles Olcott in 1833 and is headquartered in Irving, TX.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest MCK news

Apr 16 12:20am ET Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), McKesson (MCK) Mar 25 8:25pm ET Notable companies reporting before tomorrow’s open Mar 25 1:47pm ET Notable companies reporting before tomorrow’s open Mar 17 6:44am ET McCormick stock about to shake things up, Barron’s says Mar 12 7:16am ET Rockwell Automation announces Stephen Ford as chief information security officer Mar 06 7:59am ET McKesson price target raised to $620 from $575 at UBS Feb 26 7:20am ET Analysts Are Bullish on Top Healthcare Stocks: BeiGene (BGNE), McKesson (MCK) Feb 26 6:21am ET McKesson initiated with an Outperform at Leerink Feb 14 5:12pm ET Third Point buys McKesson, exits T-Mobile in Q4 Feb 14 10:01am ET FTC probing drug distributors over low supplies of chemotherapies, WSJ reports Feb 12 5:50am ET Analysts Offer Insights on Healthcare Companies: McKesson (MCK), Embecta Corporation (EMBC) and Abbott Labs (ABT) Feb 09 6:57am ET McKesson price target raised to $505 from $450 at Mizuho Feb 09 6:24am ET McKesson price target raised to $575 from $559 at UBS Feb 09 5:50am ET McKesson price target raised to $571 from $537 at Barclays Feb 08 6:45am ET McKesson price target raised to $567 from $519 at Baird Feb 08 6:31am ET Analysts Offer Insights on Healthcare Companies: McKesson (MCK), Arcus Biosciences (RCUS) and Neurocrine (NBIX) Feb 08 6:27am ET McKesson price target raised to $571 from $537 at Barclays Feb 08 6:02am ET Analysts Conflicted on These Healthcare Names: McKesson (MCK), Arcturus Therapeutics (ARCT) and Neurocrine (NBIX) Feb 08 5:50am ET McKesson price target raised to $575 from $530 at Citi Feb 08 5:30am ET Analysts Offer Insights on Healthcare Companies: Azenta (AZTA), Neurocrine (NBIX) and McKesson (MCK) Feb 08 12:15am ET McKesson’s Strong Earnings and Positive Growth Outlook Merit a Buy Rating Feb 07 4:15pm ET McKesson raises FY24 adjusted EPS view to $27.25-$27.65, consensus $27.32 Feb 07 4:13pm ET McKesson reports Q3 adjusted EPS $7.74, consensus $7.05 Feb 07 3:25pm ET McKesson options imply 3.9% move in share price post-earnings Feb 07 1:18pm ET Notable companies reporting after market close Feb 02 1:46pm ET Buy/Sell: Wall Street’s top 10 stock calls this week Jan 24 7:00am ET McKesson price target raised to $564 from $514 at JPMorgan

No recent press releases are available for MCK

MCK Financials

1-year income & revenue

Key terms

MCK Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

MCK Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms